Access to anti-retroviral drugs, male in Iraq

Iraq: Access to anti-retroviral drugs, male was 65.0% in 2024. ▲ Rising

Latest (2024)
65.0%
Change on year
up 14.0%
World rank
83rd
of 141 countries
All-time high
65.0%
in 2024
All-time low
22.0%
in 2009
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Iraq, 2000–2024

2030405060702000201220242000: 46 %2001: 38 %2002: 34 %2003: 31 %2004: 28 %2005: 27 %2006: 26 %2007: 25 %2008: 23 %2009: 22 %2010: 22 %2011: 22 %2012: 22 %2013: 24 %2014: 26 %2015: 28 %2016: 33 %2017: 41 %2018: 45 %2019: 46 %2020: 46 %2021: 51 %2022: 56 %2023: 57 %2024: 65 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, male in Iraq is 65.0%, measured in 2024. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 14.0% on the previous year and up 150.0% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Iraq peaked at 65.0% in 2024 and was at its lowest, 22.0%, in 2009.

That places Iraq 83rd out of 141 countries with data for 2024, putting it in the middle of the range.

The long-run direction has been consistently rising across the 25 years of available data.

Access to anti-retroviral drugs, male in Iraq, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Iraq, 2000 to 2024.
Year % Change
2000 46.0%
2001 38.0% -17.4%
2002 34.0% -10.5%
2003 31.0% -8.8%
2004 28.0% -9.7%
2005 27.0% -3.6%
2006 26.0% -3.7%
2007 25.0% -3.8%
2008 23.0% -8.0%
2009 22.0% -4.3%
2010 22.0% +0.0%
2011 22.0% +0.0%
2012 22.0% +0.0%
2013 24.0% +9.1%
2014 26.0% +8.3%
2015 28.0% +7.7%
2016 33.0% +17.9%
2017 41.0% +24.2%
2018 45.0% +9.8%
2019 46.0% +2.2%
2020 46.0% +0.0%
2021 51.0% +10.9%
2022 56.0% +9.8%
2023 57.0% +1.8%
2024 65.0% +14.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 30.0% 22.0% 46.0% 10
2010s 30.9% 22.0% 46.0% 10
2020s 55.0% 46.0% 65.0% 5

Countries ranked near Iraq

  1. 80 Cuba 66.0% compare
  2. 80 Guyana 66.0% compare
  3. 80 Slovakia 66.0% compare
  4. 83 Morocco 65.0% compare
  5. 83 Oman 65.0% compare
  6. 83 Serbia 65.0% compare

See the full ranking of 160 places →

More gender data for Iraq

All data for Iraq →

Frequently asked questions

What is access to anti-retroviral drugs, male in Iraq?
Access to anti-retroviral drugs, male in Iraq was 65.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Iraq?
The highest recorded value was 65.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Iraq?
The lowest recorded value was 22.0% in 2009.
How does Iraq rank for access to anti-retroviral drugs, male?
Iraq ranks 83rd out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Iraq?
Over the last ten years it is up 150.0%. The long-run trend across the full record is rising.
Where does this Iraq data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Iraq. Statizoid, drawing on UNAIDS estimates. Retrieved 10 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/iraq/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/iraq/">Access to anti-retroviral drugs, male in Iraq</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.